Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes
Background: Real-world outcomes for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab in combination with taxane chemotherapy plus trastuzumab (TaxTP) in the first line setting and trastuzumab emtansine (TE) in any line of t...
Main Authors: | Sasha Lupichuk, Winson Y Cheung, Douglas Stewart |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-10-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.1177/1178223419879429 |
Similar Items
-
Efficacy of trastuzumab-emtansine in breast cancer patients prior treated with pertuzumab
by: Sundfors, Anu-Johanna
Published: (2019) -
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
by: Barrios, C., et al.
Published: (2022) -
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
by: Sara Lonardi, et al.
Published: (2020-10-01) -
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
by: Sara A. Hurvitz, et al.
Published: (2012-09-01) -
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
by: Sawaki M
Published: (2014-04-01)